Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories maintains a strong financial outlook, bolstered by an impressive customer retention rate of approximately 97%, which enhances revenue and earnings predictability. The company has achieved a compound annual growth rate (CAGR) of about 16% for organic consumables revenue from 2016 to 2022, indicating robust growth in its recurring consumables segment. Additionally, the expectation of increased clinical visits over the long term, combined with the potential for accelerated adoption of its testing products amid a recovering pet market, positions IDEXX for further market expansion.

Bears say

IDEXX Laboratories has experienced a consistent decline in clinical vet visits, with a year-over-year decrease of -1.7% reported in Q4'25, following similar declines in previous quarters, indicating a worrying trend in veterinary services. The company anticipates a further reduction of 200 basis points in pet visits for 2026, largely attributed to economic challenges facing lower-income pet owners, which could hinder demand for IDEXX’s diagnostic products and services. Additionally, financial hardships among customers and suppliers may exacerbate cash flow issues, potentially impacting sales and the overall growth of IDEXX's market presence.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $715, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $715, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.